Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Carina Biotech to Present Preclinical Data Evaluating
Preclinical data demonstrates that LGR5-targeting CAR-T therapy…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Evaluating
HARMAN and American Center for Mobility (ACM) Announce Strategic Collaboration at MWC 2023,…
With this strategic effort, HARMAN is tapping into ACM’s real-world driving environments equipped with connected infrastructure and Multi-access Edge Computing (MEC) services for evaluating road-ready connected vehicle products through 5G…
Coresight Research Launches Innovator Matrix Series Evaluating Growth Companies
Initial report ranks top 10 last-mile delivery companies based on Level of Innovation and Market Potential
NEW YORK--(BUSINESS WIRE)--Coresight Research (Coresight) announces the launch of the Innovator Matrix report series. Coresight is…
Helsinn announces publication of new data evaluating
<!-- Name:DistributionId Value:1000780622 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value: -->…
ProSomnus® Enrolls First Participant in Study Evaluating
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the enrollment of the first…
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination…
– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression –
- Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized…
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with…
- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF)
- Initial results of a Phase 1/2 study…
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s…
– Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’s –
– The level of beta-amyloid removal by gantenerumab was lower than expected –
– Topline data will be…
Apros Therapeutics to Present Interim Clinical Data from a Phase 1 Study Evaluating APR003 at the…
SAN DIEGO--(BUSINESS WIRE)--Apros Therapeutics, Inc., a clinical stage biotechnology company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of advanced cancers and infectious diseases, today announced…
Vir Biotechnology Presents New Data Evaluating the
– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – – Preliminary data to-date show that 30.8%…